Serous Endometrial Intraepithelial Carcinoma: Case Report and Literature Review

Kawata, Mayuko; Miyoshi, Anderson; Fujikawa, Eri; Kanao, Serika; Takeda, Masatoshi; Mimura, Mayuko; Nagamatsu, Masaaki; Yokoi, Takeshi

doi:10.14740/jcgo446w

Cited by 3 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serous endometrial intraepithelial carcinoma (SEIC), a malignant lesion associated with p53 mutation in a background of atrophic endometrium, has been postulated to be a precursor of uterine serous carcinoma [ 44 , 45 ]. SEIC has been identified in 40–89% of patients diagnosed with serous endometrial cancer [ 46 , 47 , 48 , 49 ]. Furthermore, concordant genetic mutations have been demonstrated in both components of SEIC and serous endometrial cancer [ 50 ].…”

Section: Discussionmentioning

confidence: 99%

Endometrial Cancer and BRCA Mutations: A Systematic Review

Gasparri

Bellaminutti

Farooqi

et al. 2022

JCM

View full text Add to dashboard Cite

This systematic review identifies, evaluates, and summarises the findings of all relevant individual studies on the prevalence of BRCA mutation (BRCAm) in endometrial cancer patients and the incidence of endometrial cancer in BRCAm women patients. Consequently, the benefits and limits of a prophylactic hysterectomy at the time of the risk-reducing salpingo-oophorectomy are analysed and discussed. A systematic literature search was performed in the databases of PubMed, Cochrane, and Web of Science until May 2022; 13 studies met the eligibility criteria. Overall, 1613 endometrial cancer patients from 11 cohorts were tested for BRCA1/2 mutation. BRCA1/2m were identified in 4.3% of women with endometrial cancer (70/1613). BRCA1m was the most represented (71.4%) pathogenic variant. Alongside, a total of 209 BRCAm carriers from 14 studies were diagnosed with endometrial cancer. Only 5 out of 14 studies found a correlation between BRCAm and an increased risk of endometrial cancer. Nevertheless, two studies found a statistical difference only for BRCA1m women. The present systematic review does not provide strong evidence in favour of performing routine hysterectomy at the time of risk-reducing salpingo-oophorectomy; however, it provides epidemiological data that can be useful for counselling patients in order to offer a tailored approach.

show abstract

Section: Discussionmentioning

confidence: 99%

Endometrial Cancer and BRCA Mutations: A Systematic Review

Gasparri

Bellaminutti

Farooqi

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…In 46 of 81 patients, there was no evidence of disease at the end of follow-up, 12 patients were alive with the disease, 18 patients died from the disease and 2 patients died from other causes. In two studies, 62.5% and 33.3% of patients receiving adjuvant chemotherapy, respectively, relapsed [2,10], while, in three studies, none of the patients relapsed [3,12,14]. Among patients not receiving any adjuvant treatment, only in one study were no relapses reported [13], and the average recurrence rate was 28.78%, ranging from 16.6% to 100%, and the DFS was 59.1%.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, although the benefits of adjuvant treatments are not yet clear [21,22], it appears necessary to opt for additional treatments or close follow-up in patients who have undergone incomplete surgical staging. Adjuvant treatments were adopted in most cases in patients with advanced stages of the disease, except for one study in which the more aggressive approach could be justified by the young age of the patient examined, albeit with stage IA disease [12]. The patients who were followed had promising results.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Critical Overview of Serous Endometrial Intraepithelial Cancer Treatment: Systematic Review of Adjuvant Options

Ronsini,

Reino,

Molitierno

et al. 2023

Life

View full text Add to dashboard Cite

SEIC is a non-invasive lesion of the endometrial epithelium considered to be the precursor to uterine serous carcinoma (USC) and is just as aggressive as USC. Currently, there are no reliable data about the behavior and prognosis of SEIC; therefore, the therapeutic management approach is not clear. Method: A systematic search of the Pubmed, Scopus and Embase databases was conducted, following the recommendations in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results: Of the 296 studies that matched the search criteria, only 9 met the inclusion criteria, covering a total of 81 patients. The main disease-presenting pattern was AUB (abnormal uterine bleeding). In 31 cases, SEIC was associated with extrauterine disease. All patients underwent hysterectomy and salpingo-oophorectomy, while only 15 of the 81 patients received adjuvant treatments. In the patients receiving adjuvant therapy, the RR was 42.67%, the DFS was 35.71% and the OS was 57.13%. In patients subjected to follow-up alone, the RR was only 28.78%, the DFS was 59.1% and the OS was 66.6%. Conclusions: The presence of an extrauterine disease significantly worsens outcomes, regardless of adjuvant treatment. In cases of disease confined to the uterine mucosa alone, the prognosis is good and follow-up allows a good control of the disease; however, adjuvant therapy could further increase survival rates and reduce relapse rates.

show abstract

“…Sherman et al 4 and Kawata et al 13 suggested that EIC was the major precursor of serous endometrial carcinoma seen in 100 per cent of ESC with concurrent EIC. In the present study, we observed 48 out of 120 patients with EIC in the adjacent endometrium as well as five cases of non-invasive carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Endometrial serous carcinoma: A retrospective review of histological features & their clinicopathological association with disease-free survival & overall survival

Agarwal

Yadav

Dusane

et al. 2022

Indian Journal of Medical Research

View full text Add to dashboard Cite

Background & objectives: Endometrial serous carcinoma (ESC) is a high-grade epithelial neoplasm with increased risk for metastasis and recurrence. This study was aimed to assess various histomorphological features of ESC and their clinicopathological association with disease-free survival (DFS) and overall survival (OS). Methods: A total of 205 slides (belonging to 120 patients) diagnosed as ESC from January 2009 to December 2015 were reviewed. Receiver operating characteristics (ROC) curves were established for the diagnostic performance of depth of invasion (DOI), tumour-free distance (TFD) to serosa and percentage myometrial invasion (MI%). OS and DFS were generated by Kaplan-Meier curves and prognostic significance by Cox regression analysis. Results: The mean age at diagnosis was 61.8 yr and the mean tumour size was 4.01 cm. Majority of the females were multiparous (84%; n=94) and postmenopausal (89.2%; n=107). On histopathology, <50 per cent of MI was identified in 37 of the 104 (35%), while 62/104 (59.61%) patients had ≥50 per cent MI. Seven (6.7%) patients had full-thickness invasion with serosal involvement, while five (4.8%) patients had no microscopic MI (minimal uterine serous carcinoma). Information about MI was not available in 16 patients. TFD ≥7.0 mm, DOI ≥6.0 mm and MI% ≥40 were significant variables in univariate analyses for OS; however, on multivariate analysis; none of these turned out to be an independent predictor in terms of OS. For DFS, DOI (≥6.0 mm) and MI% (≥40%) showed a significant association, in univariate as well as multivariate analysis; however, TFD (≤7.0 mm) did not show any significant association with DFS. Follow up data were available in 111 of the 120 (92.5%) patients with a five-year OS and DFS of 22.2 and 17.2 per cent, respectively. Interpretation & conclusions: Conventionally calculated DOI (less than or more than half thickness) did not show significance in the present study. Thus, calculating the actual myometrial DOI, MI% and TFD to serosa have the potential for contributing meaningfully to prognostication of ESC.

show abstract

Serous Endometrial Intraepithelial Carcinoma: Case Report and Literature Review

Cited by 3 publications

References 11 publications

Endometrial Cancer and BRCA Mutations: A Systematic Review

Endometrial Cancer and BRCA Mutations: A Systematic Review

Critical Overview of Serous Endometrial Intraepithelial Cancer Treatment: Systematic Review of Adjuvant Options

Endometrial serous carcinoma: A retrospective review of histological features & their clinicopathological association with disease-free survival & overall survival

Contact Info

Product

Resources

About